Damien R. Ashby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Damien R. Ashby has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Peter Choi
9 shared publications- Neill Duncan
Imperial College London
6 shared publications - Daniel Philip Gale
Department of Renal Medicine, University College London
5 shared publications - Patrick Henry Maxwell
Cambridge Institute for Medical Research, Department of Medicine, University of Cambridge, Cambridge, UK
5 shared publications - Mark Busbridge
Department of Clinical Chemistry, Hammersmith Hospital, London, UK
4 shared publications David H. Taube
Imperial College Kidney and Transplant Institute Hammersmith Hospital London United Kingdom
3 shared publications
Latest Publications
- 14 February 2019
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 14 (3) , 378-384
Central Venous Stenosis, Access Outcome and Survival in Patients undergoing Maintenance Hemodialysis
Background and objectives Central venous catheters have traditionally provided access for urgent hemodialysis, but are also sometimes advocated as an option for older or more comorbid patients. Adverse effects of this type of dialysis access include central venous stenosis, for which the risk factors and consequences are incompletely understood. Design, setting, participants, & measurements We conducted two studies within the same population cohort, comprising all patients starting hemodialysis in a single center from January 2006 to December 2013. First, patients were retrospectively analyzed for the presence of central venous stenosis; their access outcomes are described and survival compared with matched controls drawn from the same population. Second, a subset of patients with a history of catheter access within this cohort was analyzed to determine risk factors for central venous stenosis. Results Among 2811 patients, central venous stenosis was diagnosed in 120 (4.3%), at a median dialysis vintage of 2.9 (interquartile range, 1.8–4.6) years. Compared with matched controls, patients with central venous stenosis had similar survival (median 5.1 versus 5.2 years; P=0.54). Among a subset of 500 patients, all with a history of catheter use, 34 (6.8%) developed central venous stenosis, at a rate of 2.2 per 100 patient-years. The incidence of central venous stenosis was higher with larger number of previous catheters (relative risk [RR], 2.2; 95% confidence interval [95% CI]. 1.6 to 2.9), pacemaker insertion (RR, 3.9; 95% CI, 1.7 to 8.9), and was lower with older age (RR, 0.7 per decade; 95% CI, 0.6 to 0.8). In a Cox proportional hazards model, the catheter number, pacemaker, and younger age at dialysis initiation were all significant independent risk factors for central venous stenosis. Conclusions Central venous stenosis occurred in a minority of patients on hemodialysis, and was associated with compromised future access, but unchanged survival. Among patients with a history of catheter use, risk related to both the number of catheters and the total catheter duration, although nondialysis factors such as pacemakers were also important. Central venous stenosis risk was lower in older patients, supporting the selective use of tunneled catheters in this group. Visual Abstract
- 14 February 2019
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 14 (3) , 378-384
Central Venous Stenosis, Access Outcome and Survival in Patients undergoing Maintenance Hemodialysis
Background and objectives Central venous catheters have traditionally provided access for urgent hemodialysis, but are also sometimes advocated as an option for older or more comorbid patients. Adverse effects of this type of dialysis access include central venous stenosis, for which the risk factors and consequences are incompletely understood. Design, setting, participants, & measurements We conducted two studies within the same population cohort, comprising all patients starting hemodialysis in a single center from January 2006 to December 2013. First, patients were retrospectively analyzed for the presence of central venous stenosis; their access outcomes are described and survival compared with matched controls drawn from the same population. Second, a subset of patients with a history of catheter access within this cohort was analyzed to determine risk factors for central venous stenosis. Results Among 2811 patients, central venous stenosis was diagnosed in 120 (4.3%), at a median dialysis vintage of 2.9 (interquartile range, 1.8–4.6) years. Compared with matched controls, patients with central venous stenosis had similar survival (median 5.1 versus 5.2 years; P=0.54). Among a subset of 500 patients, all with a history of catheter use, 34 (6.8%) developed central venous stenosis, at a rate of 2.2 per 100 patient-years. The incidence of central venous stenosis was higher with larger number of previous catheters (relative risk [RR], 2.2; 95% confidence interval [95% CI]. 1.6 to 2.9), pacemaker insertion (RR, 3.9; 95% CI, 1.7 to 8.9), and was lower with older age (RR, 0.7 per decade; 95% CI, 0.6 to 0.8). In a Cox proportional hazards model, the catheter number, pacemaker, and younger age at dialysis initiation were all significant independent risk factors for central venous stenosis. Conclusions Central venous stenosis occurred in a minority of patients on hemodialysis, and was associated with compromised future access, but unchanged survival. Among patients with a history of catheter use, risk related to both the number of catheters and the total catheter duration, although nondialysis factors such as pacemakers were also important. Central venous stenosis risk was lower in older patients, supporting the selective use of tunneled catheters in this group. Visual Abstract
- 1 May 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 87 (5) , 231-236
Hepcidin clearance is associated with erythropoietin requirement in stable hemodialysis patients
The discovery of hepcidin, the hormone regulating iron absorption and transport, has improved the understanding of anemia and erythropoietin treatment. Excessive hepcidin signaling causes anemia in chronic inflammatory conditions by restricting iron delivery to the bone marrow. Hepcidin is normally eliminated in the urine, and the high levels seen in renal failure are thought to contribute to renal anemia and resistance to erythropoietin.
- 1 May 2017
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology
- Vol. 87 (5) , 231-236
Hepcidin clearance is associated with erythropoietin requirement in stable hemodialysis patients
The discovery of hepcidin, the hormone regulating iron absorption and transport, has improved the understanding of anemia and erythropoietin treatment. Excessive hepcidin signaling causes anemia in chronic inflammatory conditions by restricting iron delivery to the bone marrow. Hepcidin is normally eliminated in the urine, and the high levels seen in renal failure are thought to contribute to renal anemia and resistance to erythropoietin.
- 6 August 2013
- Published by Wiley in Clinical Transplantation
- Vol. 27 (5) , 649
Effect of initial dialysis access on post-transplant outcome
- 6 August 2013
- Published by Wiley in Clinical Transplantation
- Vol. 27 (5) , 649
Effect of initial dialysis access on post-transplant outcome
- 23 August 2012
- Published by Springer Nature
- p. 231-256
Ghrelin in Cachexia Associated with End-Stage Renal Disease
- 23 August 2012
- Published by Springer Nature
- p. 231-256
Ghrelin in Cachexia Associated with End-Stage Renal Disease
- 1 November 2009
- Published by Elsevier in Kidney International
- Vol. 76 (10) , 1116
Response to ‘Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease’
- 1 November 2009
- Published by Elsevier in Kidney International
- Vol. 76 (10) , 1116
Response to ‘Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease’
- Open Access
- 14 October 2009
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (3) , 505-508
Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin
Expression of hepcidin, the key hormone governing iron transport, is reduced by anemia in a manner which appears dependent on increased bone marrow activity. The temporal associations between plasma hepcidin and other iron parameters were examined in healthy humans after erythropoietin administration and venesection. Profound hepcidin suppression appeared abruptly 24 hours after subcutaneous erythropoietin (P=0.003), and was near maximal at onset, with peak (mid-afternoon) levels reduced by 73.2%, gradually recovering over the following two weeks. Minor changes in circulating iron, soluble transferrin receptor and growth differentiation factor-15 were observed after the reduction in hepcidin. Similar but more gradual changes in these parameters were observed after reducing hematocrit by removal of 250 mL blood. These human studies confirm the importance of a rapidly responsive marrow–hepcidin axis in regulating iron supply in vivo, and suggest that this axis is regulated by factors other than circulating iron, soluble transferrin receptor or growth differentiation factor-15.
- 14 October 2009
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 95 (3) , 505-508
Open AccessErythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin
Expression of hepcidin, the key hormone governing iron transport, is reduced by anemia in a manner which appears dependent on increased bone marrow activity. The temporal associations between plasma hepcidin and other iron parameters were examined in healthy humans after erythropoietin administration and venesection. Profound hepcidin suppression appeared abruptly 24 hours after subcutaneous erythropoietin (P=0.003), and was near maximal at onset, with peak (mid-afternoon) levels reduced by 73.2%, gradually recovering over the following two weeks. Minor changes in circulating iron, soluble transferrin receptor and growth differentiation factor-15 were observed after the reduction in hepcidin. Similar but more gradual changes in these parameters were observed after reducing hematocrit by removal of 250 mL blood. These human studies confirm the importance of a rapidly responsive marrow–hepcidin axis in regulating iron supply in vivo, and suggest that this axis is regulated by factors other than circulating iron, soluble transferrin receptor or growth differentiation factor-15.
- Open Access
- 1 October 2009
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (10) , 1601-1605
Bacteremia Associated with Tunneled Hemodialysis Catheters
Background and objectives: Treatment without catheter replacement (catheter salvage) has been described for bacteremia associated with tunneled venous catheters in hemodialysis patients, but few data are available on which to base an estimation of the likelihood of treatment success. Design, setting, participants, & measurements: In a prospective cohort study, all cases of catheter-associated bacteremia that occurred in a large dialysis center were identified during a 12-mo period. Catheter salvage was attempted according to a standard protocol in all cases in which a favorable early response to antibiotic therapy was seen, and patients were followed for at least 6 mo. Bacteremias, catheter changes, and all major clinical events were recorded. Results: During a period covering 252,986 catheter days, 208 episodes were identified involving 133 patients, 74% of which were selected for attempted salvage. Salvage was successful in 66.1% of incident bacteremias with a very low complication risk (0.9%). Some bacteremias, however, recurred as late as 6 mo after the initial infection; salvage was less likely to be successful in treating recurrences. Conclusions: Appropriately used catheter salvage can be successful in approximately two thirds of cases; however, recurrences continue to occur up to 6 mo later and are unlikely to be cured without catheter replacement.
- 1 October 2009
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 4 (10) , 1601-1605
Open AccessBacteremia Associated with Tunneled Hemodialysis Catheters
Background and objectives: Treatment without catheter replacement (catheter salvage) has been described for bacteremia associated with tunneled venous catheters in hemodialysis patients, but few data are available on which to base an estimation of the likelihood of treatment success. Design, setting, participants, & measurements: In a prospective cohort study, all cases of catheter-associated bacteremia that occurred in a large dialysis center were identified during a 12-mo period. Catheter salvage was attempted according to a standard protocol in all cases in which a favorable early response to antibiotic therapy was seen, and patients were followed for at least 6 mo. Bacteremias, catheter changes, and all major clinical events were recorded. Results: During a period covering 252,986 catheter days, 208 episodes were identified involving 133 patients, 74% of which were selected for attempted salvage. Salvage was successful in 66.1% of incident bacteremias with a very low complication risk (0.9%). Some bacteremias, however, recurred as late as 6 mo after the initial infection; salvage was less likely to be successful in treating recurrences. Conclusions: Appropriately used catheter salvage can be successful in approximately two thirds of cases; however, recurrences continue to occur up to 6 mo later and are unlikely to be cured without catheter replacement.
- 1 October 2009
- Published by Elsevier in Kidney International
- Vol. 76 (8) , 912-913
Response to ‘The utility of multivariate analysis in the study of hepcidin’
- 1 October 2009
- Published by Elsevier in Kidney International
- Vol. 76 (8) , 912-913
Response to ‘The utility of multivariate analysis in the study of hepcidin’
- 1 September 2009
- Published by Elsevier in Kidney International
- Vol. 76 (6) , 680-681
Response to ‘Hepcidin levels in patients with renal disease’
- 1 September 2009
- Published by Elsevier in Kidney International
- Vol. 76 (6) , 680-681
Response to ‘Hepcidin levels in patients with renal disease’
- Open Access
- 1 July 2009
- Published by Elsevier in Kidney International
- Vol. 76 (2) , 199-206
Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment
- 1 July 2009
- Published by Elsevier in Kidney International
- Vol. 76 (2) , 199-206
Open AccessSustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment